Mounting discontents of some foreign firms over the insurance price re-assessment

Published: 2002-05-24 06:59:00

Updated: 2002-05-24 06:59:00

The Ministry of Health and Welfare says that some pioneer drugs of foreign invested firms, which are intended to be re-listed as insurance drugs by switching their local production into importation, will be subjected to a 80 percent pricing level lower than their originally listed insurance price...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK